ADMA Biologics, Inc. Unveils Key Updates in 8-K Filing – February 2025
Based on the provided section of the financial report, here are the key pieces of information extracted:
- Entity Information:
- Company Name: ADMA Biologics, Inc.
- CIK (Central Index Key): 0001368514
- State of Incorporation: Delaware (DE)
- SEC File Number: 001-36728
- Employer Identification Number (EIN): 56-2590442
- Address: 465 State Route 17, Ramsey, NJ 07446
- Phone Number: 201-478-5552
- Filing Type:
- Form: 8-K (Current Report)
- Filing Date: February 19, 2025
- Stock Information:
- Common Stock Ticker Symbol: ADMA
- Stock Exchange: NASDAQ
- Period of Reporting:
- Start Date: February 19, 2025
- End Date: February 19, 2025
- XBRL and Schema Information:
- XML Version: 1.0
- XBRL Namespace: http://www.xbrl.org/2003/instance
- Schema Reference: adma-20250219.xsd
Insights:
- This filing indicates that ADMA Biologics, Inc. is reporting significant events or changes to its stakeholders as required by the SEC through an 8-K form.
- The report is focused on a single day (February 19, 2025), suggesting that the information being reported is likely time-sensitive or related to a specific event occurring on that date.
- Given that this is a current report, it may include critical information such as changes in management, financial results, or other significant corporate developments that are essential for investors and analysts to consider.
These details can be used to monitor the company’s activities and assess its financial health and operational changes in the near term.